title: Clinical study on effect of Garlicin in stabilizing the carotid artery atherosclerotic plaque in patients with primary hypertension and coronary artery disease.
abstract: OBJECTIVE
  To investigate the effect of garlicin in treating carotid artery atherosclerotic plaque (CAAP) in patients with primary hypertension and coronary heart disease (PHT-CHD).
  
  
  METHODS
  Seventy-nine patients with PHT-CHD were randomly divided into the treated group (39 patients) treated with garlicin and fosinopril and the control group (40 patients) treated with fosinopril alone. The change of CAAP was evaluated by high frequency ultrasonic examination every six months, and the changes of intercellular adhesion molecule-1 (ICAM-1) and high sensitive C-reactive protein (hs-CRP) were measured by ELISA, with the observation proceeding for 52 weeks totally.
  
  
  RESULTS
  By the end of the experiment, the number of complex plaques, Crouse integrals, intima-media thickness, serum ICAM-1 and hs-CRP were significantly lower in the treated group than those in the control group with significant difference (P < 0.05).
  
  
  CONCLUSIONS
  Garlicin could stabilize CAAP to a certain extent and shows a definite vascular protective effect in patients with PHT-CHD.
authors.affiliation: Department of National Integrative Medicine Center for Cardiovascular Diseases, China-Japan Friendship Hospital, Beijing, China. chch20000@yahoo.com.cn
authors.forename: Wen-li
authors.initials: WL
authors.lastname: Cheng
authors.forename: Yuan-nan
authors.initials: YN
authors.lastname: Ke
authors.forename: Zai-xiang
authors.initials: ZX
authors.lastname: Shi
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Chen
authors.forename: Gao
authors.initials: G
authors.lastname: Ju
authors.forename: Shu-ying
authors.initials: SY
authors.lastname: Fan
mesh_terms: D000368:Aged; D000498:Allyl Compounds / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D002097:C-Reactive Protein / Q000378:metabolism; D002340:Carotid Artery Diseases / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003324:Coronary Artery Disease / Q000150:complications / Q000188:drug therapy*; D004220:Disulfides / Q000008:administration & dosage*; D005260:Female; D017328:Fosinopril / Q000008:administration & dosage; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D008297:Male; D008875:Middle Aged; D014463:Ultrasonography
chemical_list: D000498:Allyl Compounds; D000959:Antihypertensive Agents; D004220:Disulfides; D018799:Intercellular Adhesion Molecule-1; C028009:diallyl disulfide; D002097:C-Reactive Protein; D017328:Fosinopril